Securities Code: 002099
Securities Abbreviation: Haixiang Pharmaceutical
Announcement Number: 2026-037
Zhejiang Haixiang Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
I. Overview of Partnership Investment
The 12th meeting of the 6th Board of Directors of Zhejiang Haixiang Pharmaceutical Co., Ltd. reviewed the proposal on participating in the establishment of a partnership to invest in Fuhong Hanlin, agreeing to invest 100 million RMB to participate in the establishment of Taizhou Fuhong Equity Partnership (Limited Partnership) [now renamed: Hangzhou Fuhong Equity Investment Partnership (Limited Partnership), hereinafter referred to as "the Partnership"], holding a 64.10% share in the Partnership. This Partnership is a special fund specifically investing in non-listed shares of Shanghai Fuhong Hanlin Biotechnology Co., Ltd. (stock abbreviation: "Fuhong Hanlin", stock code: 02696). These shares were converted into H shares on February 4, 2026, and have been listed on the Hong Kong Stock Exchange. For specific details, please refer to the announcements published on June 5, 2021, and February 6, 2026, in the Securities Times, China Securities Journal, Shanghai Securities Journal, and Securities Daily (Announcement No.: 2021-023, Announcement No.: 2026-008).